Kenvue is expected to report Q1 2026 revenue of $3.84 billion and adjusted EPS of $0.27, as the stock trades around $17.44 against an average analyst price target of $19.33.
Investors are primarily focused on organic sales growth, specifically whether the company's "Extraordinary Powers" strategy is successfully driving a recovery in the Skin Health and Beauty segment following last year's declines.
The report is significantly overshadowed by the pending $48.7 billion acquisition of Kenvue by Kimberly-Clark, which has dominated the corporate narrative and led management to cancel the typical post-earnings conference call. Analysts are also closely monitoring the progress of the "Our Vue Forward" initiative, which aims to deliver $350 million in structural cost savings by the end of the 2026 fiscal year.